South Africa Pharmaceuticals and Healthcare Report Q2 2008

Publication Date	April 2008
Publisher	Business Monitor
Product Type	Report
Pages	92
ISBN Number	1748-2194
Product Code	BMI01552

Price

£425.00
approximately: $750 | €539

PDF immediate delivery

Order above formats by FAX

Summary

South Africa is one of the most promising pharmaceutical markets on the African continent.

Consequently, the country is found in a joint third position, alongside the much smaller market of Bahrain, out of the 14 Middle East and Africa (MEA) markets surveyed in BMI's Business Environment Rating table for Q208. Its large population and a considerable disease burden - including both communicable and non-communicable diseases -offer considerable opportunities in terms of pharmaceutical revenues. However, a relatively unfavourable country structure and risky pharmaceuticalspecific regulatory environment continue to represent barriers to investment.

Nevertheless, BMI forecasts a strong annual growth over the forecast period, with the generics sector reaping most benefits. Cost containment measures by the government are set to favour the cheapest treatments, as authorities aim to improve access to medicines. In addition, the pending announcement of a new National Health Reference Price List (NHRPL) for 2008 for health costs in the private sector is due to increase transparency, but also to exert a downward pressure on pharmaceutical prices to control the spiralling costs of private sector insurance. However, the Department of Health appears to have disregarded consumer price data that suggests rising prices when putting together the NHRRL for 2008.

The list will recommend an average rise in private healthcare fees of 5.4% , which falls below inflation levels. Consequently, the affordability of medicines remains in question.

In the meantime, pressure on public healthcare resources seems to have been compounded by pricefixing.

In February 2008, the South African Competition Commission accused four pharmaceutical firms of colluding to inflate their prices for government hospital tenders and acting as a cartel. One of the companies in question, Adcock Ingram, had previously been linked with similar deals through its parent company Tiger Brands. In November 2007, Tiger Brands was fined for its participation in bread and milling cartels. The investigation is set to have a negative effect on Adcock Ingram's planned spin-off.

In other industry news, in November 2007, local Aspen Pharmacare signed a strategic partnership with India's active pharmaceutical ingredients (APIs) manufacturer Strides Arcolab. The deal will interlink the two companies' interests across several regions and therapeutic areas. Aspen, already the Southern Hemisphere's largest generics firm, will take a 50% stake in Strides' Latin American operations, Strides Latina, which includes Cellofarm in Brazil, Solara in Mexico and Sumifarma in Venezuela. The move confirms the strength of the leading South African generic players on a global market.

Content

Executive Summary
- South Africa Political SWOT
- South Africa Economic SWOT
- South Africa Business Environment SWOT
- Pharmaceutical Business Environment Ratings
- Limits To Potential Returns
- Risks To Realisation Of Returns
- South Africa - Market Summary
- Regulatory Regime
- Recent Regulatory Developments
- Intellectual Property Environment
- Compulsory Licensing
- Counterfeit Activity
- Pricing System
- Reimbursement System
- Recent Pricing And Reimbursement Developments
- Industry Developments
- Epidemiology
- HIV/AIDS
- Tuberculosis
- Healthcare Sector
- Recent Healthcare Sector Developments
- Health Insurance
- Government Health Insurance
- Recent Insurance Industry Developments
- Pharmaceutical Sector
- ARV Manufacturing and Government Tenders
- Domestic Company Developments
- Key Facts: Stategic Partnership Between Strides Arcolab And Aspen Pharmacare
- Foreign Company Developments
- Retail Pharmacy Sector
- Research And Development Sector
- AIDS/HIV Research
- Vaccines
- Traditional African Medicine
- Medical Devices
- Regional Developments in Medical Devices Sector
- Medical Devices Forecasts
- Industry Forecast Sce51
- Overall Market Forecast
- Key Growth Factors - Industry
- Key Growth Factors - Macroeconomic
- Patented Market Forecast
- Generics Market Forecast
- OTC Market Forecast
- Export/Import Forecasts
- Other Healthcare Data
- Key Risks To BMI's Forecast Scenario
- Competitive Landscape
- Company Monitor
- Leading Foreign Companies
- Sanofi-Aventis
- Pfizer
- Roche
- GlaxoSmithKline
- Bayer
- Merck & Co
- Leading Indigenous Manufacturers
- Aspen Pharmacare
- Adcock Ingram
- Enaleni Pharmaceuticals
- BMI Forecast Modelling
- How We Generate Our Industry Forecasts
- Pharmaceutical Industry
- Pharmaceutical Business Environment Ratings Methodology
- Ratings Overview
- Weighting
- Sources
List of Tables
- Table: Pharmaceutical Business Environment Ratings
- Table: Companies Involved In South Africa's February 2008 Price Fixing Scandal
- Table: Leading Causes Of Disease In Africa, 2002
- Table: PIASA Membership
- Table: Results Of South Africa's HIV/AIDS Drug Tender, March 2005
- Table: South African Customs Classification Of Medical Devices
- Table: Aims Of PEPFAR-BD Partnership
- Table: South Africa's Medical Device Market, 2005-2012 (US$mn unless otherwise stated)
- Table: Drug Expenditure And Prescription Market Indicators (US$mn unless otherewise stated)
- Table: Health Expenditure Indicators, 2006-2012
- Table: South Africa - Economic Activity
- Table: South Africa's Prescription Drug Market Forecast Indicators (US$mn unless otherwise stated)
- Table: Generic Drug Market, 2006-2012
- Table: South Africa's OTC Drug Market Indicators (US$mn unless otherwise stated)
- Table: South Africa's Export And Import Trade Indicators (US$mn)
- Table: General Healthcare Indicators
- Table: Top 10 Drugmakers In South Africa, 2006
- Table: Pharmaceutical Business Environment Indicators
- Table: Weighting Of Components

About this Product

Delivery Details

PDF:Immediate delivery

Ask a question about this product?

Need help finding the right product?

Product features / use

Scope	Expert Insight/Opinion
Level	General Industry Strategies
Data	Detailed Market Forecasts
Profiles	Profiles of Key Companies
Features	Contains SWOT Analysis
Extra Info	Consumer Trends Highlighted